Published in Blood Weekly, April 15th, 2004
DCs are "potent antigen-presenting cells that can induce effective tumor-specific T-cell responses," hematologists in Spain noted.
In a recent study, J. Sanchez and colleagues at University Hospital Reina Sofia in Cordoba "investigated leukapheresis products as sources of DC precursors in 48 patients undergoing autologous peripheral blood stem-cell (PBSC) transplantation for hematological malignancies."
"Strikingly, high-dose cytarabine and etoposide plus granulocyte colony stimulating factor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2004-04-15)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.